Codexis, Inc.

Greetings and welcome to the Codex's third quarter 2025 earnings conference call. At this time, all participants are in a listen-only mode. A question and answer session will follow a formal presentation. If anyone should require operator assistance during this conference, please press star zero on your telephone keypad. Please note that this conference is being recorded. I will now turn the conference over to your host, Georgia Urbez. Chief Financial Officer. Thank you. You may begin.

Thank you, Operator. With me today are Dr. Stephen Dilley, CEO and Chairman, Dr. Allison Moore, Chief Technical Officer, and Britton Jimenez, Senior Vice President, Sales and Marketing, who will be available for Q&A to follow. During this call, we will be making a number of forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including our guidance for 2025 revenue anticipated milestones, including product launches, pilot scale manufacturing, and paths to scale up, technical milestones, and public announcements related thereto, as well as our strategies and prospects for revenue growth, path to profitability, and successful execution of current and future programs and partnerships. To the extent that statements contained in this call are not descriptions of historical facts regarding Codexys, they are forward-looking statements reflecting our beliefs, and expectations as of the statement date, November 6, 2025. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors that are in some cases beyond Codex's control and that could materially affect actual results. Additional information about factors that could materially affect actual results can be found in Codex's filings with the Securities and Exchange Commission Codex has expressly disclaimed any intent or obligation to update these forward-looking statements except as required by law. And now I'll turn the call over to Stephen.

Thank you, Georgia, and thanks, everyone, for joining. We've had a very exciting and important few months that have set us up extremely well for the changes we're announcing today. First, we were very pleased to sign the Supply Assurance Agreement with Merck. We've been working on this for months, and it was a key reason why we had the confidence in our revenue projections for the year. More importantly, it was one of the final pieces of the jigsaw we needed to fall into place for us to be ready to commit to the transformation of Codexis into a full-service manufacturing innovator in the field of oligonucleotide manufacturing. We also expect to sign the lease for our new facility in the next week or two. which will give us the capability to manufacture GMP-grade SARNA in kilogram quantities using our EcoSynthesis technologies. We're really excited by the commercial trajectory of the Eco platform. This time last year, we were closing in on our first revenue-bearing contract. Today, we have 11, with 40 more in the pipeline. The technical team has continued to make spectacular progress on perfecting and scaling the eco platform, and we will be presenting new data at Tides Europe next week. So in summary, we have the financial resources, the real estate, the expertise, and the demand lined up to move Cadexis into the next phase of our transition. On a personal note, this completes the task I came here to do as CEO. Over the past three years, in an effort expertly led by Kevin Norritt, we've conducted a thorough assessment of the most attractive markets that can be accessed using our co-devolver technology. About two years ago, we got very excited about the enzymatic synthesis of siRNA, an endeavor that led to the Ecosynthesis platform you see today. Now that we are confident in the market and the potential of the platform, The time is right to optimize and streamline the organization to maximize our ability to succeed. Evolving from an enzyme supplier to an innovative manufacturing solutions provider allows us to streamline our existing organization. This will significantly reduce our cost base while improving our responsiveness and nimbleness and allowing us to build further for the future. We've looked to optimize every level of the organization. With that in mind, I'm extremely excited that Alison Moore, our chief technical officer, will succeed me as CEO. I intend to remain with Codexis as executive chair. There's a saying that successful CDMOs are run by leaders with deep technical expertise. Alison is a great leader and has deep experience and expertise in perfecting and scaling novel manufacturing platforms. Similarly, Kevin has handed over the commercial reins to Brittain Jimenez, a domain expert in commercial leadership of CDMOs. Brittain is here on the call to answer your commercial questions. With that, I'm going to hand over to Alison.